These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 34351500)

  • 1. Performance evaluation of the new chemiluminescent intact FGF23 assay relative to the existing assay system.
    Kato H; Hidaka N; Koga M; Ogawa N; Takahashi S; Miyazaki H; Nangaku M; Makita N; Ito N
    J Bone Miner Metab; 2022 Jan; 40(1):101-108. PubMed ID: 34351500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical performance of a new intact FGF23 immunoassay in healthy individuals and patients with chronic hypophosphatemia.
    Kato H; Miyazaki H; Kimura T; Hoshino Y; Hidaka N; Koga M; Nangaku M; Makita N; Ito N
    Bone Rep; 2023 Jun; 18():101659. PubMed ID: 36817167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical performance of a novel chemiluminescent enzyme immunoassay for FGF23.
    Ito N; Kubota T; Kitanaka S; Fujiwara I; Adachi M; Takeuchi Y; Yamagami H; Kimura T; Shinoda T; Minagawa M; Okazaki R; Ozono K; Seino Y; Fukumoto S
    J Bone Miner Metab; 2021 Nov; 39(6):1066-1075. PubMed ID: 34255195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of FGF23-related hypophosphatemic osteomalacia by alcohol consumption.
    Hidaka N; Kato H; Koga M; Katsura M; Oyama Y; Kinoshita Y; Fukumoto S; Makita N; Nangaku M; Ito N
    Bone Rep; 2021 Dec; 15():101144. PubMed ID: 34901334
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intact Fibroblast Growth Factor 23 Concentrations in Hypophosphatemic Disorders.
    Ramos P; Larson B; Ashrafzadeh-Kian S; Ito N; Kato H; Bornhorst JA; Algeciras-Schimnich A
    Endocr Pract; 2023 Mar; 29(3):193-198. PubMed ID: 36627024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical usefulness of measurement of fibroblast growth factor 23 (FGF23) in hypophosphatemic patients: proposal of diagnostic criteria using FGF23 measurement.
    Endo I; Fukumoto S; Ozono K; Namba N; Tanaka H; Inoue D; Minagawa M; Sugimoto T; Yamauchi M; Michigami T; Matsumoto T
    Bone; 2008 Jun; 42(6):1235-9. PubMed ID: 18396126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determination of FGF23 Levels for the Diagnosis of FGF23-Mediated Hypophosphatemia.
    Hartley IR; Gafni RI; Roszko KL; Brown SM; de Castro LF; Saikali A; Ferreira CR; Gahl WA; Pacak K; Blau JE; Boyce AM; Salusky IB; Collins MT; Florenzano P
    J Bone Miner Res; 2022 Nov; 37(11):2174-2185. PubMed ID: 36093861
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sensitivity of fibroblast growth factor 23 measurements in tumor-induced osteomalacia.
    Imel EA; Peacock M; Pitukcheewanont P; Heller HJ; Ward LM; Shulman D; Kassem M; Rackoff P; Zimering M; Dalkin A; Drobny E; Colussi G; Shaker JL; Hoogendoorn EH; Hui SL; Econs MJ
    J Clin Endocrinol Metab; 2006 Jun; 91(6):2055-61. PubMed ID: 16551733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. X-Linked Hypophosphatemia and FGF23-Related Hypophosphatemic Diseases: Prospect for New Treatment.
    Kinoshita Y; Fukumoto S
    Endocr Rev; 2018 Jun; 39(3):274-291. PubMed ID: 29381780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FGF23 concentrations vary with disease status in autosomal dominant hypophosphatemic rickets.
    Imel EA; Hui SL; Econs MJ
    J Bone Miner Res; 2007 Apr; 22(4):520-6. PubMed ID: 17227222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Iron and fibroblast growth factor 23 in X-linked hypophosphatemia.
    Imel EA; Gray AK; Padgett LR; Econs MJ
    Bone; 2014 Mar; 60():87-92. PubMed ID: 24325979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early Discrimination Between Tumor-Induced Rickets/Osteomalacia and X-Linked Hypophosphatemia in Chinese Children and Adolescents: A Retrospective Case-Control Study.
    Jiajue R; Ni X; Jin C; Huo L; Wu H; Liu Y; Jin J; Yu W; Lv W; Zhou L; Xia Y; Chi Y; Cui L; Pang Q; Li X; Jiang Y; Wang O; Li M; Xing X; Meng X; Xia W
    J Bone Miner Res; 2021 Sep; 36(9):1739-1748. PubMed ID: 33971042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Rickets/Osteomalacia. Anti-FGF23 antibody therapy in patients with FGF23-related hypophosphatemic rickets and osteomalacia.].
    Kinoshita Y
    Clin Calcium; 2018; 28(10):1373-1379. PubMed ID: 30269120
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of a new automated chemiluminescence immunoassay for FGF23.
    Shimizu Y; Fukumoto S; Fujita T
    J Bone Miner Metab; 2012 Mar; 30(2):217-21. PubMed ID: 21898178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FGF23-related hypophosphatemic rickets/osteomalacia: diagnosis and new treatment.
    Fukumoto S
    J Mol Endocrinol; 2021 Feb; 66(2):R57-R65. PubMed ID: 33295878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum FGF23 levels in normal and disordered phosphorus homeostasis.
    Weber TJ; Liu S; Indridason OS; Quarles LD
    J Bone Miner Res; 2003 Jul; 18(7):1227-34. PubMed ID: 12854832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia.
    Jonsson KB; Zahradnik R; Larsson T; White KE; Sugimoto T; Imanishi Y; Yamamoto T; Hampson G; Koshiyama H; Ljunggren O; Oba K; Yang IM; Miyauchi A; Econs MJ; Lavigne J; Jüppner H
    N Engl J Med; 2003 Apr; 348(17):1656-63. PubMed ID: 12711740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of a New Fully Automated Assay for Plasma Intact FGF23.
    Souberbielle JC; Prié D; Piketty ML; Rothenbuhler A; Delanaye P; Chanson P; Cavalier E
    Calcif Tissue Int; 2017 Nov; 101(5):510-518. PubMed ID: 28761972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nationwide survey of fibroblast growth factor 23 (FGF23)-related hypophosphatemic diseases in Japan: prevalence, biochemical data and treatment.
    Endo I; Fukumoto S; Ozono K; Namba N; Inoue D; Okazaki R; Yamauchi M; Sugimoto T; Minagawa M; Michigami T; Nagai M; Matsumoto T
    Endocr J; 2015; 62(9):811-6. PubMed ID: 26135520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Chronic bone pain due to raised FGF23 production? The importance of determining phosphate levels].
    de Jongh RT; Vervloet MG; Bravenboer N; Heijboer AC; den Heijer M; Lips P
    Ned Tijdschr Geneeskd; 2013; 157(28):A5908. PubMed ID: 23841927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.